Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 13, 2024
Discovery & Translation
Science spotlight: Tumors siphon taurine from T cells, and Revolution’s RAS (ON) inhibitors
BioCentury’s roundup of translational innovations
BioCentury | Sep 22, 2023
Distillery Therapeutics
Noncovalent inhibitor targeting multiple KRAS mutations in cancer
BioCentury | May 12, 2023
Emerging Company Profile
Vevo: scaling up in vivo discovery of cancer targets
Backed by Wing Venture Capital and General Catalyst, Vevo is modeling many patients’ tumors in single mice
BioCentury | Apr 25, 2023
Product Development
KRAS’s next chapter: hitting the target’s active form
Investors rewarded Revolution for preclinical KRAS (ON) data at AACR23, as a wave of dual KRAS (ON/OFF) inhibitors at the meeting gear up for the clinic
BioCentury | Jul 9, 2019
Finance
Revolution raises $100M to build out Ras pipeline, explore SHP-2 combos
How Revolution Medicines plans to deploy Boxer Capital-led series C to advance portfolio of Ras pathway inhibitors
Items per page:
1 - 10 of 45